Hepatitis D laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatitis D}} | {{Hepatitis D}} | ||
{{CMG}}; {{ | {{CMG}}; {{AE}} {{JM}} {{JS}} | ||
==Overview== | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Line 69: | Line 71: | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 18:15, 7 August 2014
Hepatitis D |
Diagnosis |
Treatment |
Hepatitis D laboratory findings On the Web |
American Roentgen Ray Society Images of Hepatitis D laboratory findings |
Risk calculators and risk factors for Hepatitis D laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jolanta Marszalek, M.D. [2] João André Alves Silva, M.D. [3]
Overview
Laboratory Findings
The table below describes the significance of diagnostic markers in HDV infection. [1]
Diagnostic Markers | Significance |
---|---|
Anti-HDV IgG antibody |
|
Anti-HDV IgM antibody |
|
HDV RNA |
Qualitative
Quantitative
|
HBsAg |
Qualitative
Quantitative
|
HBeAg |
|
HBV DNA |
Quantitative
|
ALT |
|
References
- ↑ Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
- ↑ Heidrich B, Manns MP, Wedemeyer H (2013). "Treatment options for hepatitis delta virus infection". Curr Infect Dis Rep. 15 (1): 31–8. doi:10.1007/s11908-012-0307-z. PMID 23242761.